Watch List for Traders: Arena Pharmaceuticals, Inc., Philip Morris International (NYSE:PM), Vericel Corporation (NASDAQ:VCEL), Legacy Reserves LP (NASDAQ:LGCY)

AK Steel Holding Corporation (NYSE:AKS) ended the last trading day at $4.01. Company weekly volatility is calculated as 11.70% and price to cash ratio as 12.64. AK Steel Holding Corporation (NYSE:AKS) showed a weekly performance of 7.22%.

On 4 March, AK Steel Holding Corporation (NYSE:AKS) said it would increase base prices for its carbon flat-rolled steel products by a minimum $30 a metric ton, a move similar to increases announced to customers by other big steelmakers, including Nucor Corp., U.S. Steel Corp. and ArcelorMittal.

On 11 March, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares increased 2.74% and was closed at $1.50. ARNA EPS growth in last 5 year was 17.00%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is -21.05%.

On 29 February, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported financial results for the fourth quarter and full year ended December 31, 2015, and provided a corporate update. Revenues totaled $38.3 million, including $19.7 million in net product sales of BELVIQ.

Philip Morris International, Inc. (NYSE:PM) shares decreased -0.36% in last trading session and ended the day at $96.49. PM Gross Margin is 65.00% and its has a return on assets of 20.80%. Philip Morris International, Inc. (NYSE:PM) quarterly performance is 10.92%.

Philip Morris International, Inc. (NYSE:PM) declared a regular quarterly dividend of $1.02 per common share, payable on April 11, 2016, to shareholders of record as of March 25, 2016. The ex-dividend date is March 22, 2016.

Vericel Corporation (NASDAQ:VCEL) caters to the Healthcare space. It has a net profit margin of -40.60% and weekly performance is 119.80%. On the last day of trading company shares ended up at $4.33. Vericel Corporation (NASDAQ:VCEL) distance from 50-day simple moving average (SMA50) is 4.83%.

Vericel Corporation (NASDAQ:VCEL) announced top-line results from the company’s Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM). The trial met its primary endpoint of demonstrating a reduction in the total number of deaths, cardiovascular hospitalizations or unplanned outpatient and emergency department visits to treat acute decompensated heart failure during the 12 months following treatment with ixmyelocel-T compared to placebo.

Legacy Reserves LP (NASDAQ:LGCY) caters to the Basic Materials space. Its weekly performance is 34.09%. On the last day of trading company shares ended up at $1.18. Legacy Reserves LP (NASDAQ:LGCY) distance from 50-day simple moving average (SMA50) is 16.74%.

Wells Fargo lowered shares of Legacy Reserves LP (NASDAQ:LGCY) from a market perform rating to an underperform rating in a research report sent to investors on Thursday morning, The Fly reports.